Coultreon Biopharma Accelerates Clinical Development of SIK3 Inhibitor for Autoimmune Diseases

Belgium-based Coultreon Biopharma has secured $125 million (approximately $172 billion KRW) in a Series A funding round to accelerate the clinical development of 'COL-5671,' an oral SIK3 inhibitor for the treatment of autoimmune diseases. This round was led by Sofinnova Investments, with participation from Galapagos (GLPG), which had previously transferred the asset. COL-5671 was originally developed by Galapagos and transferred to Coultreon through an asset transfer agreement last year. This significant funding will accelerate its progression from Phase 1 to Phase 2 clinical trials.

Vivacta Biotechnology Develops In Vivo CAR-T Platform for Enhanced Patient Convenience

Shanghai-based Vivacta Biotechnology has successfully completed Series A and A+ funding rounds, raising over $50 million (approximately $69 billion KRW), to support the clinical development of its in vivo CAR-T cell therapy pipeline, 'GT801.' GT801 is a CD19-targeted therapy designed to target B-cell malignancies and autoimmune diseases directly within the patient's body, utilizing a T-cell targeted lipid nanoparticle (T-LNP) platform technology. By eliminating the complex and costly ex vivo manufacturing process, GT801 is poised to be a game-changer in the next-generation CAR-T therapy market.

Significant Unmet Needs and Growth Potential in Autoimmune and Hematological Cancer Markets

The psoriasis treatment market is currently estimated at $23.6 billion to $36.9 billion by 2026, and the ulcerative colitis market is estimated at $8.7 billion to $11.3 billion, both demonstrating continued growth. Existing biological therapies, such as TNF-alpha inhibitors, often require injections, leading to lower patient convenience and limitations due to the development of resistance. This has created a strong demand for new oral small molecule therapies with novel mechanisms of action. Similarly, the CAR-T therapy market for hematological cancers is rapidly expanding, reaching approximately $4.8 billion by 2026. The commercialization of in vivo technologies that significantly reduce costs and production time is expected to trigger a rapid shift in the market.

Venture Capital Bets on Innovative Technologies and Platform-Oriented Approaches Amidst Global Investment Downturn

Despite recent global interest rate and macroeconomic uncertainties, there is a clear trend of large amounts of capital being concentrated in companies with distinct technological differentiation and promising late-stage clinical candidates. In particular, the case of Galapagos, which spun off its core assets in exchange for equity and milestone payments, demonstrates a mutually beneficial strategy of streamlining pipelines for large pharmaceutical companies and enabling rapid development by specialized ventures. Investors are increasingly focusing on high-value platform technologies that can potentially dominate the market upon commercialization, rather than short-term risks.